Funding period

Sept 2020 - Aug 2022



from Ovarian Cancer Canada

About the project

High-grade serous ovarian cancer (HGSOC) stands as the most prevalent and deadly gynecological cancer in the Western world, presenting a formidable challenge in terms of effective treatment. In our recent investigations, we’ve pinpointed a gene (RBX1) and pathway (SCF pathway) that we suspect play pivotal roles in altering chromosome numbers—a crucial factor in driving the formation and progression of HGSOC. Through a comprehensive approach blending genetics, biochemistry, cell biology, and cutting-edge imaging techniques, we aim to delve deeper into the workings of this gene and pathway within cell models. Our goal is to uncover how they influence chromosome numbers and contribute to the genesis and advancement of HGSOC.

Furthermore, armed with this newfound understanding, we intend to identify novel drug targets capable of selectively eliminating cancer cells exhibiting reduced RBX1 expression. By shedding light on the underlying mechanisms driving HGSOC, our study seeks to pave the way for the discovery of novel therapeutic targets and the development of advanced strategies to combat this relentless disease. Ultimately, our efforts aim to improve HGSOC patient lives and outcomes.

The Manitoba Ovarian Cancer Research program team

The Manitoba Ovarian Cancer Research program team